Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BioSig Technologies, Inc. (BSGM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.08000.0000 (0.00%)
At close: 1:00PM EST
3.0600 -0.02 (-0.65%)
After hours: 03:18PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close3.0800
Open3.0400
Bid3.0600 x 800
Ask3.1000 x 1800
Day's Range3.0000 - 3.1099
52 Week Range2.2600 - 6.1400
Volume109,221
Avg. Volume222,633
Market Cap108.757M
Beta (5Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)-1.0360
Earnings DateNov 18, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BSGM

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioSig Technologies, Inc.
    Weekly Stock ListVickers Stock Research, a subsidiary of Argus Research Group, tracks and analyzes insider trading and institutional ownership trends. Form 13-Fs are due 45 days after the end of calendar quarters, and have now come in from 2Q21. We like to review the 13Fs of the major activist investors, including Carl Icahn, Trian Fund Management, Jana Partners, and ValueAct Holdings, among others. Activist investing has evolved in recent years and is now less about generating a short-term return on an underpriced stock and more about achieving long-term returns through an active management/investor partnership. Here are some recent new purchases and key holdings of activist investors, according to Vickers.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    BioSig to Participate in the The Benchmark Company 10th Annual Discovery Conference

    Westport, CT, Nov. 17, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would participate in The Benchmark Company 10th Annual Discovery One on One Investor Conference (Virtual) on Thursday, December 2, 2021. The Company’s executive leadership wil

  • GlobeNewswire

    BioSig Initiates Artificial Intelligence Development Program with Technion – Israel Institute of Technology

    Company partners with the leading academic institution on research and development of AI-driven methods for atrial fibrillation proceduresWestport, CT, Nov. 16, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company entered into a fe

  • GlobeNewswire

    BioSig to Host Live Roundtable Webinar to Discuss Clinical Data Delivered With Its Signal Processing Technology For Arrhythmia Care

    Discussion led by three industry experts scheduled for November 18, 2021 at 8pm ETWestport, CT, Nov. 11, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it will host a live roundtable webinar to discuss the PURE EP 2.0 study results recently publish

Advertisement
Advertisement